Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Bioprojet Pharma

Home Clinical Trial Sponsors and OrganizationsBioprojet Pharma

Bioprojet Pharma

Unknown Belgian address, Unknown, Belgium

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

29

14 active

Approvals

20

Total approvals

Agencies

3

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

25

86.2%

Phase 2

2

6.9%

Phase 3

1

3.5%

Trial Status Distribution

Active, not recruiting

14

48.3%

Completed

6

20.7%

Recruiting

8

27.6%

Withdrawn

1

3.5%

Clinical Trials

Trials sponsored by this organization (29)

Open label, single-center, two-part pharmacokinetic study:Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects.Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

May 202432 participants

A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in adult patients with eosinophilic esophagitis.

Active, not recruiting

Mar 202424 participants

Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects

Nov 202320 participants

1206d849eb8f9b8b

Aug 202384 participants

A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder.

Active, not recruiting

Aug 202386 participants

Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations versus the reference pitolisant (Wakix®) tablet formulation after single oral administrations in healthy male subjects.

Active, not recruiting

Jul 202316 participants

An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.

May 202366 participants

Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.

Active, not recruiting

Apr 202375 participants

Page 1 of 4

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

5

Approvals

EMA

European Medicines Agency

4

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

11

Approvals

Recent Approvals

TIORFAN INFANTIL 4 MG/ML SUSPENSIÓN ORAL

Pitolisant Hydrochloride Tablets

Pitolisant Hydrochloride Tablets

OZAWADE 4,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

OZAWADE 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

AMGLIDIA 0,6 mg/ml SUSPENSION ORAL

AMGLIDIA 6 mg/ml SUSPENSION ORAL

Racecadotril Powder

News

No news articles found

On this page

Overview
Clinical Trials29
Approvals20
News

Back to Organizations